Sign in

    Arslan Cameron

    Research Analyst at ROTH Capital Partners

    Arslan Cameron serves as an Equity Research Analyst at ROTH Capital Partners, specializing in coverage of growth-oriented companies across the healthcare and medical device sectors. He has been featured asking in-depth questions about Sensus Healthcare and other companies on quarterly earnings calls, demonstrating active engagement and sector knowledge. While specific performance metrics such as TipRanks rankings or average returns are not publicly available, Cameron's research contributions reflect a focus on detailed revenue and product performance analysis for firms like Sensus Healthcare. Details on his career timeline, including his start date at ROTH and prior employment history, as well as his professional licenses or FINRA registration, are not available from public sources.

    Arslan Cameron's questions to Sensus Healthcare (SRTS) leadership

    Arslan Cameron's questions to Sensus Healthcare (SRTS) leadership • Q4 2024

    Question

    Inquired about the competitive landscape, the operational ramp-up time and capacity for new Fair Deal Agreement (FDA) sites, the characteristics of customers choosing FDAs over direct purchase, and the sales concentration with the company's largest customer.

    Answer

    The competitive landscape is stable, with Mohs surgery as the main alternative. The FDA program is particularly attractive to large, private equity-backed groups that want to preserve capital for practice acquisitions. The company uses analytics to help these groups select high-volume sites for initial placements. Regarding the largest customer, they accounted for 25 of the 39 units delivered in Q4 and are expected to continue purchasing in 2025.

    Ask Fintool Equity Research AI